Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
NCT ID: NCT03488706
Last Updated: 2018-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2018-01-17
2021-06-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Markers for Early Detection of Prostate Cancer
NCT00340717
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
NCT03237026
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
NCT00373035
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer
NCT03927287
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
NCT04825002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gray Zone Group
The gray zone group PSA between 4.00 to 10.99 ng/ml.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age from 20 to 99 years old
* Subjects with a PSA 4.00- 10.99 ng/ml and will receive biopsy within 3 months
Exclusion Criteria
* Refuse to sign the informed consent form
* Received regional anesthesia and general anesthesia within one month
* Previous cancer history
* Autoimmune diseases
* Chronic inflammatory diseases
* Diagnosed with colorectal polyps or adenomas
* Acute inflammatory or infectious diseases in three months
* Other diseases decided by PI
20 Years
99 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CellMaxLife
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying-Hsu Chang
Role: PRINCIPAL_INVESTIGATOR
Chang Gung Memorial Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Linkou Chang Gung Memorial Hospital
Taoyuan, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ying-Hsu Chang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMx-CTC-PC-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.